Multi-input Optimal Control Problems for Combined Tumor Anti-angiogenic and Radiotherapy Treatments

Journal of Optimization Theory and Applications

Volumn 153, Issue 1, 2012, Pages 195-224

  Ledzewicz, U ^a   Schattler H ^b  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^b WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

Anti angiogenic treatments; Combination therapy; Optimal control; Radiotherapy; Totally singular controls

Indexed keywords

OPTIMAL CONTROL SYSTEMS; POPULATION STATISTICS; STRUCTURAL OPTIMIZATION; TUMORS;

ANTI-ANGIOGENIC TREATMENT; CELL POPULATIONS; COMBINATION THERAPY; MULTIINPUT; OPTIMAL CONTROL PROBLEM; OPTIMAL CONTROLS; RADIOTHERAPY TREATMENT; SINGULAR CONTROL; TOTALLY SINGULAR CONTROL; TUMOR VOLUMES;

RADIOTHERAPY;

EID: 84857916870     PISSN: 00223239     EISSN: 15732878     Source Type: Journal    
DOI: 10.1007/s10957-011-9954-8     Document Type: Article

References (51)

1. Folkman, J.: Antiangiogenesis: new concept for therapy of solid tumors. Ann. Surg., 175, 409-416 (1972).
2. Kerbel, R. S.: Tumor angiogenesis: past present and near future. Carcinogensis, 21, 505-515 (2000).
3. Boehm, T., Folkman, J., Browder, T., O'Reilly, M. S.: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407 (1997).
4. Kerbel, R. S.: A cancer chemotherapy resistant to resistance. Nature 390, 335-336 (1997).
5. d'Onofrio, A.: Fractal growth of tumors and other cellular populations: linking the mechanistic to the phenomenological modeling and vice versa. Chaos Solitons Fractals 41, 875-880 (2009).
6. Jain, R. K.: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987-989 (2001).
7. Jain, R. K., Munn, L. L.: Vascular normalization as a rationale for combining chemotherapy with antiangiogenic agents. Princ. Pract. Oncol. 21, 1-7 (2007).
8. Qian, D., et al.: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Research, 64 (2004); see also: http://www. hopkinsmedicine. org/Press_releases/2004/09_16_04. html.
9. Eisen, M.: Mathematical Models in Cell Biology and Cancer Chemotherapy. Lecture Notes in Biomathematics, vol. 30. Springer, Berlin (1979).
10. Swan, G. W.: Role of optimal control in cancer chemotherapy. Math. Biosci. 101, 237-284 (1990).
11. Swierniak, A.: Optimal treatment protocols in leukemia-modelling the proliferation cycle. Proc. 12th IMACS World Congress, Paris 4, 170-172 (1988).
12. de Pillis, L. G., Radunskaya, A.: A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. J. Theor. Med. 3, 79-100 (2001).
13. Fister, K. R., Panetta, J. C.: Optimal control applied to cell-cycle-specific cancer chemotherapy. SIAM J. Appl. Math. 60, 1059-1072 (2000).
14. Ledzewicz, U., Schättler, H.: Optimal bang-bang controls for a 2-compartment model in cancer chemotherapy. J. Optim. Theory Appl. 114, 609-637 (2002).
15. Ledzewicz, U., Schättler, H.: Analysis of a cell-cycle specific model for cancer chemotherapy. J. Biol. Syst. 10, 183-206 (2002).
16. Ledzewicz, U., Schättler, H.: Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy. Math. Biosci. 206, 320-342 (2007).
17. Hahnfeldt, P., Panigrahy, D., Folkman, J., Hlatky, L.: Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59, 4770-4775 (1999).
18. Ergun, A., Camphausen, K., Wein, L. M.: Optimal scheduling of radiotherapy and angiogenic inhibitors. Bull. Math. Biol. 65, 407-424 (2003).
19. Schättler, H., Ledzewicz, U., Cardwell, B.: Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis. Math. Biosci. Eng. 8, 355-369 (2011).
20. d'Onofrio, A., Gandolfi, A.: The response to antiangiogenic anticancer drugs that inhibit endothelial cell proliferation. Appl. Math. Comput. 181, 1155-1162 (2006).
21. d'Onofrio, A., Gandolfi, A.: A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. Math. Med. Biol. 26, 63-95 (2009). doi: 10. 1093/imammb/dqn024.
22. Ledzewicz, U., Schättler, H.: Anti-angiogenic therapy in cancer treatment as an optimal control problem. SIAM J. Control Optim. 46, 1052-1079 (2007).
23. d'Onofrio, A., Ledzewicz, U., Maurer, H., Schättler, H.: On optimal delivery of combination therapy for tumors. Math. Biosci. 222, 13-26 (2009). doi: 10. 1016/j. mbs. 2009. 08. 004.
24. Swierniak, A.: Modelling combined angiogenic and chemo-therapy. In: Proc. of the Fourteenth National Conference on Appl. of Math. Biology and Medicine, Leszno, Poland, pp. 127-133 (2008).
25. Swierniak, A.: Direct and indirect control of cancer populations. Bull. Pol. Acad. Sci., Tech. Sci. 56, 367-378 (2008).
26. Ledzewicz, U., Schättler, H.: A synthesis of optimal controls for a model of tumor growth under angiogenic inhibitors. In: Proc. 44th IEEE Conf. on Dec. and Contr., Sevilla, Spain, pp. 945-950 (2005).
27. Ledzewicz, U., Munden, J., Schättler, H.: Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models. Discrete Contin. Dyn. Syst., Ser. B 12, 415-438 (2009).
28. Ledzewicz, U., Maurer, H., Schättler, H.: Bang-bang and singular controls in a mathematical model for combined anti-angiogenic and chemotherapy treatments. In: Proc. 48th IEEE Conf. on Dec. and Contr., Shanghai, China, pp. 2280-2285 (2009).
29. Kellerer, A. M., Rossi, H. H.: The theory of dual radiation action. Curr. Top. Radiat. Res. Q. 8, 85-158 (1972).
30. Chadwick, K. H., Leenhouts, H. P.: The Molecular Theory of Radiation Biology. Springer, Berlin, (1981).
31. Thames, H. D., Hendry, J. H.: Fractionation in Radiotherapy. Taylor and Francis, London (1987).
32. Fowler, J. F.: The linear-quadratic formula and progress in fractionated radiotherapy. Br. J. Radiol. 62, 679-694 (1989).
33. d'Onofrio, A.: A general framework for modelling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Physica D 208, 202-235 (2005).
34. Norton, L., Simon, R.: Growth curve of an experimental solid tumor following radiotherapy. J. Natl. Cancer Inst. 58, 1735-1741 (1977).
35. Norton, L.: A Gompertzian model of human breast cancer growth. Cancer Res. 48, 7067-7071 (1988).
36. Poleszczuk, J., Bodnar, M., Forys, U.: New approach to modeling of anti-angiogenic treatment on the basis of Hahnfeldt et al. model. Math. Biosci. Eng. 8, 591-903 (2011).
37. d'Onofrio, A., Gandolfi, A.: Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). Math. Biosci. 191, 159-184 (2004).
38. d'Onofrio, A.: Rapidly acting antitumoral anti-angiogenic therapies. Phys. Rev. E 76, 031920 (2007).
39. d'Onofrio, A., Gandolfi, A., Rocca, A.: The dynamics of tumour-vasculature interaction suggests low-dose, time-dense antiangiogenic schedulings. Cell Prolif. 42, 317-329 (2009).
40. Hanin, L. G., Zaider, M.: Cell-survival probability at large doses: an alternative to the linear-quadratic models. Phys. Med. Biol. 55, 4687-4702 (2010).
41. Wein, L. M., Cohen, J. E., Wu, J. T.: Dynamic optimization of a linear-quadratic model with incomplete repair and volume-dependent sensitivity and repopulation. Int. J. Radiat. Oncol. Biol. Phys. 47, 1073-1083 (2000).
42. Pontryagin, L. S., Boltyanskii, V. G., Gamkrelidze, R. V., Mishchenko, E. F.: The Mathematical Theory of Optimal Processes. MacMillan, New York (1964).
43. Bonnard, B., Chyba, M.: Singular Trajectories and their Role in Control Theory. Mathématiques & Applications, vol. 40. Springer, Paris (2003).
44. Bressan, A., Piccoli, B.: Introduction to the Mathematical Theory of Control. American Institute of Mathematical Sciences (2007).
45. Piccoli, B., Sussmann, H.: Regular synthesis and sufficient conditions for optimality. SIAM J. Control Optim. 39, 359-410 (2000).
46. 3. SIAM J. Control Optim. 23, 794-802 (1985).
47. Felgenhauer, U.: On stability of bang-bang type controls. SIAM J. Control Optim. 41, 1843-1867 (2003).
48. Felgenhauer, U.: Lipschitz stability of broken extremals in bang-bang control problems. In: Lirkov, I., et al. (eds.) Large-Scale Scientific Computing, Sozopol 2007. Lecture Notes in Comp. Sci., vol. 4818, pp. 317-325. Springer, Berlin (2008).
49. Maurer, H., Büskens, C., Kim, J.-H., Kaja, Y.: Optimization techniques for the verification of second-order sufficient conditions for bang-bang controls. Optim. Control Appl. Methods 26, 129-156 (2005).
50. Maurer, H., Osmolovskii, N.: Quadratic sufficient optimality conditions for bang-bang control problems. Control Cybern. 33, 555-584 (2003).
51. Brenner, D. J., Hall, E. J., Huang, T., Sachs, R. K.: Optimizing the time course of brachytherapy and other accelerated radiotherapeutic protocols. Int. J. Radiat. Oncol. Biol. Phys. 29, 893-901 (1994).